Molecular Partners AG
Galerie
Beschreibung
Our purpose is to transform the lives of people with serious diseases through our custom-built DARPin therapeutics.
We are pioneers: inventors and developers of DARPin therapeutics, an entirely new class of custom-built drugs.
As our name indicates, collaboration is in our DNA: within our team, with our partners, and with patients and providers. We build on deep trust, individual diversity, and shared passion to reach our common goal of surmounting the toughest challenges in medicine, including the treatment of cancer and other serious diseases.
Our long-term strategy leverages our in-house DARPin design and development expertise combined with the capabilities of world-class partners to deliver a broad pipeline of innovative therapeutics.
DARPin Biology
DARPins: Our class of multi-functional protein therapeutics with unique advantages
We have pioneered the class of DARPin therapeutics, which have multiple unique advantages that differentiate them from other protein-based drugs. DARPins can be linked together to a single molecule that performs multiple functions at once, opening up numerous opportunities for treating serious diseases.
By building on these innate characteristics and in-house expertise, Molecular Partners is continually unlocking and expanding the versatility of DARPin therapeutics for patients worldwide.
Manufacturing DARPins: a focus on speed and simplicity
All DARPin therapeutics are constructed to benefit from high-yield manufacturing. The ability to be produced via E.coli-based bacterial fermentation is a major advantage over other protein-based therapeutic approaches. For example, antibody drugs often require manufacturing process optimization and post-translational protein modification, which significantly increases manufacturing time and complexity. In contrast, DARPins are smaller and do not require extensive post-translational modification to enable stability or function. This permits relatively simple, highly scalable bacterial fermentation with clinical batch production every seven to ten days.
Candidate design: rapidly tailoring DARPins to target molecules
Molecular Partners draws on a vast library of trillions of different DARPins to find those that bind best to different targets. DARPins can be rapidly combined in many different ways and the resulting combinations are run through screening processes to again ensure the best performance ‘on target’. Molecular Partners can also add special technical capabilities to any particular therapeutic candidate. These are proprietary, specific combinations of DARPins that give a potentially beneficial therapeutic effect when added to a candidate, such as half-life extension or localized immune activation. Molecular Partners continues to unlock new technical capabilities and expand their use in new candidates.